Trial Profile
An Open-Label, Pilot Study to Assess the Efficacy and Safety Of AK002 (Siglec-8) in Patients with Antihistamine-Resistant Chronic Urticaria
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Mar 2024
Price :
$35
*
At a glance
- Drugs Lirentelimab (Primary)
- Indications Chronic urticaria
- Focus Therapeutic Use
- Acronyms CURSIG
- Sponsors Allakos
- 09 Aug 2023 According to an Allakos media release, Topline data expected from the Phase 2b study of subcutaneous lirentelimab in patients with CSU in late Q4 2023 to Q1 2024.
- 23 Dec 2021 Results published in the Journal of Allergy and Clinical Immunology
- 06 May 2019 Planned End Date changed from 1 Jul 2019 to 1 May 2020.